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cells against death-inducing stimuli. Here, we show that Chlamydia trachomatis infection evokes 3-
phosphoinositide-dependent protein kinase-1 (PDPK1) signaling to ensure the completion of its developmental
cycle, further leading to the phosphorylation and stabilization of MYC. Using biochemical approaches and imag-
ing we demonstrate that Chlamydia-induced PDPK1-MYC signaling induces host hexokinase II (HKII), which be-
comes enriched and translocated to the mitochondria. Strikingly, preventing the HKII interaction with
mitochondria using exogenous peptides triggers apoptosis of infected cells as does inhibiting either PDPK1 or
MYC, which also disrupts intracellular development of Chlamydia trachomatis. These findings identify a previous-
ly unknown pathway activated by Chlamydia infection, which exhibits pro-carcinogenic features. Targeting the
PDPK1-MYC-HKII-axis may provide a strategy to overcome therapeutic resistance of infection.dies; PI3K
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MYC1. Introduction
Chlamydia trachomatis is the most common sexually transmitted
bacterial infection and the leading cause of infertility (Hammerschlag,
2004). Infection is further correlated with an increased risk of invasive
cervical cancer in human papillomavirus positive women (Smith et al.,
2004) and indirect evidence further suggests a role in ovarian cancer
(Lin et al., 2011), but themolecularmechanismunderlying this remains
elusive.
Chlamydia trachomatis has a unique biphasic developmental cycle.
Upon infection, the highly infectious elementary bodies (EBs) are se-
questered within a vacuole, termed inclusion, in which they differenti-
ate into metabolically active reticulate bodies (RBs) that divide by
binary fission (Elwell et al., 2016). After 24–72 h, RBs differentiate
back into EBs that are released to start a new round of infection. Like
other obligate intracellular bacteria, Chlamydia trachomatis has a small, phosphatidylinositol
nnel; CTL2, Chlamydia
α; PARP, poly-(ADP-
ax Planck Institute for
hotmail.com
n open access article undergenome of around 1Mb (Carlson et al., 2005), which lacks the enzymes
for many metabolic pathways as well as hexokinase (Omsland et al.,
2014). It compensates for this reduced metabolic capacity by importing
phosphorylated sugars as well as other nutrients such as amino acids,
nucleotides, and lipids from the host cell (Saka and Valdivia, 2010). It
therefore depends on viable host cells to complete its life cycle and
has evolved effective strategies to protect them from apoptosis during
the course of infection (Sharma and Rudel, 2009).
We previously demonstrated that Chlamydia inhibits host cell apo-
ptosis by activating the MDM2-p53 axis to reduce p53 levels
(Gonzalez et al., 2014). This inhibition is only partial, however, suggest-
ing that there are other pathways contributing to the apoptosis resis-
tance. In addition, it is clear that p53 reduction not only keeps host
cells alive but is also directly required for successful Chlamydial replica-
tion - by stimulating the pentose phosphate pathway (PPP), shifting cel-
lular metabolism towards aerobic glycolysis to provide increased
anabolic substrates. In this way, Chlamydia is capable of exploiting the
functional interdependence between metabolic and cell survival path-
ways (Mason and Rathmell, 2011; Siegl et al., 2014). This process is
seen in many cancers, where loss of tumor suppressors or activation
of oncogenes results inmetabolic reprogrammingwith enhanced nutri-
ent uptake and glycolysis as well as resistance to apoptosis.
Several Chlamydia trachomatis-triggered signaling pathways are
known to regulate apoptosis resistance, prominently among them thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2014; Verbeke et al., 2006); (Zhong et al., 2006). PI3K, via activation of
AKT, is a major regulator of MDM2 (Ogawara et al., 2002). It also stabi-
lizes the oncogene MYC, via activation of PDPK1 (Tan et al., 2013). MYC
promotes cell growth and proliferation, acquisition of the required bio-
energetic substrates (Eilers, 1999; Hirvonen et al., 1990; Ryan and
Birnie, 1997) and shifting of metabolism towards aerobic glycolysis
and lipid synthesis (Li and Simon, 2013). One of its transcriptional tar-
gets is hexokinase II (HKII), a key enzyme for integrating energy pro-
duction and cell viability. It catalyses the first step of glycolysis (Dang
et al., 2008) to produce glucose-6-phosphate, a crucial intermediate
for many biosynthetic pathways – including the PPP (Wilson, 2003).
Key steps in metabolic re-programming in cancer consist of upregula-
tion of HKII by MYC and enhanced association with the mitochondrial
voltage-dependent anion channel (VDAC). This association leads to in-
creased rates of glycolysis and oxidative metabolism (Robey and Hay,
2006) and inhibition of competing apoptotic signals for binding to
VDAC (Majewski et al., 2004; Mason and Rathmell, 2011; Pastorino et
al., 2002).
Here,we investigatedwhether Chlamydia trachomatismodulates the
MYC-HKII axis of host cells and whether this plays a role in apoptosis
protection. We show that infection induces stabilization of MYC via
phosphorylation at serine-62 mediated by PDPK1. This leads to en-
hanced binding of HKII to mitochondria and inhibits host cell apoptosis
required for chlamydial survival. Our data provide a link between acti-
vation of PDPK1, an important component of the PI3K pathway, and
MYC protein accumulation during chlamydial infections. It provides a
rationale for the reprograming of host metabolism to promote cell
survival.
2. Materials and Methods
2.1. Human Samples, Antibodies, Cell Lines and Reagents
Human fallopian tube tissue samples were provided by the Depart-
ment of Gynecology, Charité University Hospital, Campus Virchow Clin-
ic, Berlin, Germany, with signed, informed patient consent and under
approval by the Charité Ethics Commission (EA1/002/07). Fragments
were sourced from standard surgical procedures for benign gynecolog-
ical diseases and only anatomically normal pieces were utilized for sub-
sequent experiments. Primary mesenchymal stem cells and fallopian
tube organoids were prepared from these samples as described else-
where (Abu-Lubad et al., 2014; Kessler et al., 2015).
The following antibodies were used: rabbit monoclonal antibodies
against total MYC (D84C12, 5605), total HKII (C64G5, 2867) and total
PDHK1 (C47H1, 3820), rabbit polyclonal antibodies against total
PDPK1 (3062) and anti-P-PDPK1 (Ser-241, 3061) (all Cell Signaling);
rabbit polyclonal anti-P-MYC (T58, ab28842), mouse monoclonal anti-
P-MYC (S62, 33A12E10, ab78318, both from Abcam); mouse monoclo-
nal anti-VDAC1 (B-6, sc-390996), Rho A (24C4, sc-418) and anti-MYC
(9E10, sc-40 all fromSanta Cruz Biotechnology Inc.);mousemonoclonal
anti-Chlamydia trachomatisMAb species-specific KK-12 IgG2a (supplied
byDavid Grayston, University ofWashington, Seattle); rabbit polyclonal
anti-Chlamydia genus-specific antibody (AG, 3-090, Milan Analytica),
mouse monoclonal anti-Chlamydia trachomatis Hsp60 (ALX-804-072-
R100, Enzo Life Sciences), rabbit anti-INCA antibody (Banhart et al.,
2014); goat anti-chlamydia (1990-0404, AbD Serotec); rabbit monoclo-
nal cleaved PARP (Asp214) and rabbit polyclonal anti-cleaved caspase 3
(Asp175, 9661, both from Cell Signaling). Secondary labelled antibodies
for immunofluorescence and Western immunoblot analyses were pur-
chased from Jackson ImmunoResearch Laboratories (711-165-152,
115-166-072, 111-485-144, 115-225-146), and Amersham (NA934
and NA931). BX-912 (SML1086) and clotrimazole (6019) were from
Sigma Aldrich. A cell-permeable HKII VDAC binding domain peptide
(N-HKII) was purchased from Merck (376816) and JQ1 from Cayman
Chemical (CAS 1268524-70-4). HeLa cells (ATCC CCL-2) weremaintained in RPMI-1640 medium (52400) from Gibco-Life Technolo-
gies (52400) supplemented with 10% fetal bovine serum (FBS, S0115,
Biochrom AG).
2.1.1. Chlamydia Infections
Chlamydia infections were conducted using Chlamydia trachomatis
L2 (ATCC VR-902B) at the indicated MOIs, as described previously (Al-
Zeer et al., 2013). In brief, cells were infected for 2 h at 35 °C in normal
RPMI growth medium containing 5% FCS, 2 mM glutamine, and 1 mM
sodium pyruvate. The medium was then replaced with fresh growth
medium and the cells cultured for the indicated times at 35 °C.
Fallopian tube organoids, from healthy fallopian tube epithelial tis-
sue were generated and maintained in Matrigel under control of para-
crine growth factor cocktails, as previously described (Kessler et al.,
2015). For infection with CTL2, organoids were removed from Matrigel
by washing in ice cold medium (Advance, Invitrogen), mechanically
fragmented by passing the suspension 5 times through a 20G syringe
and centrifuged at 1200 rpm. The pellet was incubatedwith CTL2 frozen
stock to achieve MOI 5 (based on the number and size of the organoids
in the starting culture) and incubated for 20 min on ice. Subsequently,
organoid fragments were seeded back into fresh Matrigel and provided
with standard growth medium.
2.1.2. Western Immunoblotting
Western immunoblotting was conducted on cell monolayers lysed
directly with SDS lysis buffer (3% 2-mercaptoethanol, 20% glycerine,
0.05% bromophenol blue, 3% SDS). Cell lysates were harvested and
boiled at 95 °C for 10 min. Equal amounts of protein were separated
using SDS-PAGE and immunoblotting as described previously (Al-Zeer
et al., 2013).
2.1.3. Infectivity Assay
Infectious progeny assays were conducted as follows. HeLa cells
seeded in 24-well plates were infected with CTL2 as described. Infected
cells were lysed at 48 h p.i. by addingNonidet P40 (NP40) at a final con-
centration of 0.06% per well. Pipetting steps were performed using a ro-
botic station (Biomek FX pipetting robot, Beckman Coulter). Lysates
were diluted in infection medium and transferred to infect fresh HeLa
cells at a final dilution of 1:40. Plates were incubated for 24 h at 35 °C
and 5% CO2 and processed for immunolabeling.
2.1.4. Small Interfering RNAs (siRNAs)
Small interferingRNAs (siRNAs) targetingMYC5′-CCCAAGGTAGTTA
TCCTTAAA-3′, HKII 5′-ACCGGTCGCTTTGAGACCAAA-3′ and5′-CACGATG
AAATTGAACCTGGT-3′, and firefly luciferase (5′-AACUUACGCUGAGUAC
UUCGA-3′) were purchased fromQiagen (Hilden, Germany). The trans-
fection of siRNAs was performed using Hyperfect transfection reagent
(Qiagen) according to the manufacturer's instructions. Cells were har-
vested to determine the knockdown efficiency and infectious progeny
using Western blot and infectivity titration assay, respectively.
2.1.5. Cytosol-Mitochondria Fractionation
Cytosolic andmitochondrial fractionswere prepared fromHeLa cells
infected with CTL2 or control cells using the Mitochondria Isolation
Kit from Thermo Scientific, in accordance with the manufacturer's
instructions).
2.1.6. Indirect Immunofluorescence
Indirect Immunofluorescence was conducted as described else-
where (Abu-Lubad et al., 2014).
2.1.7. Apoptosis Assay
HeLa cells seeded in 24-well plates were infected with CTL2 as de-
scribed for infectious progeny assay. Cells were treated with peptide at
the indicated concentrations from 24 h p.i., recombinant human TNFα
(BD Pharmingen, 554618) was added at the indicated concentrations
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ed for 5 h until harvesting, immunoblotting and immunofluorescence.
2.1.8. Antibody Conjugation
50 μl of anti-P-PDPK1 antibody (Ser-241, 3061, Cell Signaling, con-
taining 0.1 mg/ml BSA) were concentrated to 20 μl by ultrafiltration
(Amicon Ulltra-0.5 ml, Ultracel-30K). 2 μl of ATTO-550 NHS-Ester
(20 mg/ml in DMSO) were added to the protein and incubated for 4 h
at room temperature in the dark. The reaction was terminated by the
addition of 2 μl ethanolamine (1M) and incubated for 30min. The reac-
tion mixture was incubated with 50 μl (30 mg/ml) of magnetic
Dynabeads Protein G (Novex, Life Technologies) for 30 min. After re-
moval of the supernatant, the beads were washed 2 times with 1 ml
of PBS, 0.1% Tween-20. Bound antibodywas eluted with 50 μl 0.1 M gly-
cine HCl, pH 3.0. The eluate was immediately neutralized by addition of
5 μl 1 M Tris HCl (pH 7.5).
2.1.9. Treatment With Chemicals
Cellswere treatedwith different concentrations of BX-912, clotrima-
zole, N-HKII peptide and JQ1 for the indicated time points.
2.1.10. Assessment of Host Cell Viability
Briefly, cells were treated with different drugs for the indicated time
points. Then, supernatants were collected from cells at the end of the
treatment and lactate dehydrogenase colorimetric assay (Thermo Sci-
entific) was used to evaluate toxicity exerted by different drugs accord-
ing to manufacturer's instructions. In brief, extracellular release of LDH
from damaged cells converts lactate into pyruvate via NAD+ reduction
to NADH that reduces the developer to a colored product with absor-
bance at 490 nmmeasured by a microplate reader (Molecular Devices,
USA).
2.1.11. Statistical Analysis
Data were analyzed using non-parametric one-way ANOVA,
Dunnett's multiple comparison test or Student's t-test.
3. Results
3.1. Chlamydia trachomatis Infection Increases MYC Levels in Human Cells
Immunoblotting of HeLa cell lysates revealed a significant increase
in total MYC protein levels at 24 and 48 h after infection of cells with
Chlamydia trachomatis L2 (CTL2) (Fig. 1a and b). We also visualized
MYC expression in intact HeLa cells using confocal fluorescence immu-
nohistochemistry. Non-infected cells expressed MYC at basal levels,
while infected cells (identified by their large CTL2-filled inclusions)
showed increased levels of MYC at 48 h post-infection (p.i.) (Fig. 1c).
Quantification of fluorescence signal intensity by ImageJ verified that
the levels of nuclear MYC protein were significantly increased in infect-
ed monolayers, consistent with the immunoblotting data (Fig. 1d). No-
tably, we also observed an increase of MYC expression in neighboring
non-infected cells in the infected culture (Fig. 1c and d). Thus, acute
CTL2 infection exerts paracrine effects that lead to MYC induction also
in bystander cells although we cannot exclude that the inclusion-free
cells were arisen from infected cells during mitosis.
Regulation of MYC stability is mediated by phosphorylation at two
main sites, Thr-58 and Ser-62 (Sears, 2004), which are near the amino
terminus and are highly conserved in all mammalian isoforms. In re-
sponse to a growth-stimulatory signal, MYC gene expression is in-
creased, along with protein phosphorylation on the Ser-62 residue,
resulting in its stabilization (Vervoorts et al., 2006). To monitor MYC
phosphorylation, we carried out immunoblotting of CTL2-infected pro-
tein samples using specific antibodies against MYC phosphorylated at
Ser-62 or Thr-58. Notably, while the levels of MYC phosphorylated at
Ser-62 increased, levels ofMYCphosphorylated at Thr-58decreased sig-
nificantly following infection (Fig. 1a and b), suggesting that in CTL2-infected cells, too, MYC is stabilized through phosphorylation at Ser-
62. To examine the impact of CTL2 infection in non-transformed cells,
human primarymesenchymal cells (Fig. 1e–f) and fallopian tube prima-
ry epithelial organoids (Fig. 1g–h) were prepared from fallopian tubes,
surgically removed from patients undergoing procedures for benign gy-
necological disease as described previously (Abu-Lubad et al., 2014;
Kessler et al., 2015). Infection led to a significant decrease in the levels
of MYC phosphorylated at Thr-58 (Fig. 1e–h) at 48 h p.i., while levels
of MYC phosphorylated at Ser-62 were significantly increased (Fig.
1e–h).We conclude that CTL2 infection leads to an increase in the levels
of MYC in host cells by shifting the phosphorylation state towards the
stabilized form of MYC phosphorylated at Ser-62.
3.2. PDPK1 is Phosphorylated and Recruited to Chlamydia trachomatis
Inclusions
PDPK1 has recently been linked to PLK1-dependent MYC stabiliza-
tion via phosphorylation at Ser-62 (Tan et al., 2013). To monitor
PDPK1 activation and phosphorylation, we carried out immunoblotting
of CTL2-infected HeLa cells using anti-phosphorylated PDPK1 (Ser-241)
and total-PDPK1 antibodies.We observed a significant increase in phos-
phorylated PDPK1 Ser-241 at 24 and 48 h p.i. compared to non-infected
cells (Fig. 2a and b). These results prompted us to investigate the cellu-
lar localization of PDPK1phosphorylated at Ser-241 in 48 h CTL2-infect-
ed HeLa cells, using the same antibodies. PDPK1 distribution in infected
cells was similar to control, in the form of vesicular staining throughout
the cytoplasm with minor accumulation at the chlamydial inclusions
(arrowheads, Supplementary Fig. S1a). No increase in expression levels
was observed, as examined using immunoblotting (Fig. 2a and b). Sim-
ilarly, PLK1 exhibited vesicular staining throughout the cytoplasm of in-
fected cells (arrowheads, Supplementary Fig. S1b and c), in congruence
with what has been described by Sun et al. (2011), while phosphorylat-
ed PLK1 exhibited nuclear aswell as some vesicular staining throughout
the cytoplasm upon infection, with minor accumulation at the inclu-
sions (Supplementary Fig. S1b and c). By contrast, phosphorylated
PDPK1 Ser-241 was induced and recruited to the chlamydial inclusion,
suggesting that this might be an essential step for chlamydial develop-
ment (Fig. 2c). Recruitment was specific to phosphorylated PDPK1, be-
cause the cytosolic protein RhoA was not recruited to the chlamydial
inclusion at the respective time points (Supplementary Fig. S2a). Fur-
ther, phosphorylated PDPK1 recruitment was restricted to mid- and
late-stages of chlamydial development, as no significant recruitment
to the inclusion was observed at early times of infection (Supplementa-
ry Fig. 2b). Levels of MYC phosphorylated at Ser-62 were also not
increased at early infection times (Supplementary Fig. S2c) and cyclo-
heximide treatment did not inhibit the increase of MYC phosphorylated
at Ser-62 at late stages of infection (Supplementary Fig. S2d). Recruit-
ment of phosphorylated PDPK1 to the inclusion was also observed in
human primary MSCs (Fig. 2d) and human fallopian tube organoids in-
fectedwith CTL2 for 48 h (Fig. 2e). Overall, our data indicate that PDPK1
activation functions in CTL2 infection-induced signaling.
3.3. PDPK1 Activation is Required for the Phosphorylation of MYC at Ser-62
and Chlamydial Growth
To dissect the link between CTL2-induced MYC phosphorylation at
Ser-62 and PDPK1phosphorylation,we used the established pharmaco-
logical inhibitor BX912, which blocks phosphorylation of MYC at Ser-62
(Tan et al., 2013) by inhibiting PLK1. Cells were infected with CTL2 for
48 h, treatedwith BX912 (10 μM) from12h p.i., and subjected to immu-
noblotting. BX912 on its ownhad no apparent toxic effect on the host, as
measured by LDH assay (Supplementary Fig. S3a), but markedly re-
duced the degree towhich phosphorylated PDPK1 Ser-241was induced
after chlamydial infection. In linewith this, the levels of MYC phosphor-
ylated at Ser-62 were also reduced, whereas levels of total PDPK1
remained unchanged (Fig. 3a). Further, phosphorylated PDPK1, MYC,
Fig. 1.MYC is upregulated and stabilized at 24–48h p.i.with CTL2. a)Western blot showing levels of totalMYC protein aswell asMYCphosphorylated at Ser-62 or Thr-58 at 24 and 48h p.i.
in CTL2-infected (MOI 1) whole cell lysates. β-actin served as loading control. b) Band densities from a) quantified and normalized to corresponding band densities of the β-actin loading
control. Alterations in expression levels compared to non-infected controls are represented asmean fold change±SEM, *p b 0.05, **p b 0.01, t-test, n=3. c) Confocalmicroscopy images of
HeLa cells infected with CTL2 (MOI 0.5) at 44 h p.i. TotalMYC and nuclei were labelled with anti-MYC antibody and DAPI. Scale bar: 30 μm. d) Quantification ofMYC intensities revealed a
significant increase in MYC signal in cells infected with CTL2 compared to non-infected cells, irrespective of whether they harbored chlamydial inclusions. n= 14 images. Mean pixel
intensities of MYC per nuclei were quantified from confocal images with ImageJ. Black bars indicate the means ± SD, ****p b 0.0001, t-test, n ≥ 403. e–h) Western blotting analysis
from human primary fallopian mesenchymal stem cells (e) and human epithelial primary cell organoids (g) from fallopian tube, showing upregulation of total MYC protein expression
as well as MYC phosphorylated at Ser-62 between 24 and 48 h p.i. in CTL2 (MOI 1) infected whole cell lysates. β-actin served as loading control. (f and h) The band densities were
quantified and normalized to the β-actin loading control. Alterations in expression levels compared to non-infected controls are represented as fold change ± SEM, *p b 0.05, **p b
0.01, t-test, n= 3.
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BX912-treated infected monolayers were analyzed and quantified
using ImageJ. Consistentwith the immunoblotting data, BX912 inhibitor
significantly reduced the expression of MYC and MYC phosphorylated
at Ser-62 (Fig. 3b). Then, infected samples treatedwith BX912were pre-
pared for immunofluorescence microscopy using antibodies against
phosphorylated PDPK1 Ser-241. Confocal analysis confirmed that
BX912 added at 12 h p.i. was sufficient to reduce the induction of phos-
phorylated PDPK1 Ser-241 expression levels in response to infection
with CTL2 (Fig. 3c).
The induction of phosphorylated PDPK1 upon CTL2 infection
prompted us to investigate the consequences of BX912 treatment on
the formation of infectious CTL2 progeny. Cells were infected with
CTL2 for 12 h to establish infection and then treated with 10 μM
BX912 for a further 36 h. The cells were lysed and lysates used to infect
a second population of HeLa cells for 24 h. Quantifying the number of
resulting inclusions showed that therewas a dramatic decrease in infec-
tious progeny after treatment with the inhibitor, suggesting that the
pathogen was unable to complete its normal developmental cycle
(Fig. 3d). Therefore, we conclude that a functional PDPK1 signaling
pathway is necessary for proper bacterial development.
3.4. Hexokinase II is theMajor Target of the PDPK1-MYC Axis, Which is Cru-
cial for Chlamydial Growth
As MYC is known to induce HKII and we found that stabilization of
MYC upon infection depends on the PDPK1 signaling pathway (Fig.
3a), we sought to determine expression levels of HKII in infected cells
treated with PDPK1 inhibitors. Cells were infected with CTL2 for 12 h
then treated with 10 μM BX912 from 12 h p.i. for a further 36 h before
Western immunoblotting. Infection induced the expression of HKII,
which was inhibited by treatment with BX912 (Fig. 4a). Further, HKII
signals from DMSO-treated and BX912-treated infected monolayers
were analyzed and quantified using ImageJ. Consistent with the immu-
noblotting data, BX912 inhibitor significantly reduced the induction of
HKII upon CTL2 infection (Fig. 4b), suggesting that it depends on the
PDPK1 cascade. A continuous uptake of glucose and the production of
glucose-6-phosphate is known to be essential for the survival and
growth of Chlamydia trachomatis in host cells (Engstrom et al., 2015).
Therefore, we investigated the effect ofMYC inhibition on the formation
of infectious CTL2 progeny using the small molecule inhibitor JQ1
(Bandopadhayay et al., 2014). As HeLa cells overexpress MYC due to
viral insertion, JQ1 on its own had no apparent toxic effect on host
cells, as measured by LDH assay (Fig. S3a). Cells were infected with
CTL2 for 2 h, then treated with increasing concentrations of JQ1 for an-
other period of 44 h before using the cell lysates to infect a second pop-
ulation of HeLa cells for 24 h. JQ1 treatment significantly abrogated the
production of bacterial progeny (Fig. 4c). Similarly, JQ1 treatment sig-
nificantly inhibited CTL2 replication in primary cells treated with JQ1
(Supplementary Fig. S3b). Confocal microscopy further confirmed that
JQ1 treatment abrogated the expression of MYC in infected and non-in-
fected compared to untreated cells (Supplementary Fig. 3b). Treatment
with JQ1 (20 μM) 2 h p.i. with CTL2 for additional 44 h also blocked the
increase in HKII levels observed in untreated infected HeLa cells by
Western blotting (Fig. 4d), suggesting that the induction ofHKII byChla-
mydia is MYC dependent. Quantification of MYC and HKII signals from
DMSO-treated and JQ1-treated infected monolayers using ImageJ re-
vealed that JQ1 inhibitor significantly reduced the induction of MYCFig. 2. CTL2 induces PDPK1 phosphorylation downstream of PI3K. a)Western blot showing an i
CTL2-infected (MOI 1) whole cell lysates. β-actin served as loading control. b) The band densiti
loading control. Alterations in expression levels compared to non-infected controls are represen
PDPK1 phosphorylated at Ser-241, which is recruited as a rim-like structure at the inclusions
conjugated phosphorylated PDPK1 and IncA antibodies and DAPI. Scale bar: 30 μm. Asterisk
with CTL2 for 48 h p.i. (MOI 0.5) were labelled with antibodies against Chlamydia trachomatis,
e) Human primary fallopian tube epithelial organoids, infected with CTL2 for 48 h p.i. were la
and E-Cadherin. Results were similar to c). Scale bar: 30 μm.and HKII upon infection (Fig. 4e). Similar results were obtained with
humanprimaryMSCs and human fallopian tube organoids, respectively,
infected with CTL2 for 48 h (Supplementary Fig. S3d and e). In linewith
these findings, the expression of PDHK1 in infected cells was upregulat-
ed in aMYC-dependentmanner (Fig. 4d). The induction of HKII expres-
sion after infection was confirmed to be MYC-dependent using specific
RNA interference oligonucleotides against HKII and MYC (Fig. 4f).
Knockdown of HKII or MYC using RNAi abrogated bacterial replication
(Fig. 4g), indicating that MYC-induced HKII expression in infected cells
is essential for bacterial development.
3.5. Chlamydia trachomatis Infection Enhances HKII-Mitochondria Interac-
tion to Block Apoptosis
Cell survival relies on the prevention of apoptosis largely mediated
by pathways related to PI3K signaling (Franke et al., 2003; Kandel and
Hay, 1999), coupled to metabolism and the requirement of glucose
availability (Danielsen et al., 2015; Vander Heiden et al., 2001). As
HKII inhibits apoptosis by binding mitochondrial VDAC (Vyssokikh
and Brdiczka, 2003), we examined its localization in HeLa cells during
CTL2 infection by immunoblotting of cytosolic and mitochondrial frac-
tions, using VDAC as a mitochondrial marker. In infected cells, HKII
was significantly enriched and localized at mitochondria different
from non-infected cells (Fig. 5a and b). To examine the role of the
HKII-mitochondria association for chlamydial infection we used clotri-
mazole, a drug that efficiently dissociates HKII from mitochondria in
several cell models (Pastorino et al., 2002). Clotrimazole had no appar-
ent toxic effect on host cells, as measured by LDH assay, Supplementary
Fig. S3a. However, a 24 h clotrimazole treatment initiated 24 h p.i. abro-
gated chlamydial replication in a concentration-dependent manner, as
determined by progeny assay (Fig. 5c). A competitive peptide of HKII
(N-HKII) that corresponds to the N-terminal hydrophobic domain has
recently been shown to effectively displace HKII from mitochondria
(Majewski et al., 2004). Treatment of MSCs with N-HKII during 24 h
CTL2 infection significantly inhibited bacterial replication, as deter-
mined by progeny assay (Supplementary Fig. S4a). Yet, N-HKII peptide
treatment had no toxic effect on host cells according to the LDH assay
(Supplementary Fig. S3a).
To determine whether the observed HKII-mitochondria association
contributes to apoptosis resistance of CTL2-infected cells, HeLa cells
were treated with N-HKII, tumor necrosis factor-α (TNF-α) and cyclo-
heximide for 5 h, starting at 24 h p.i. Cell lysates were then examined
by immunoblotting using antibodies directed against cleaved caspase-
3 and cleaved poly-(ADP-ribose) polymerase (PARP).Whilst CTL2 infec-
tion alone conferred a significant resistance to TNF-α-induced apopto-
sis, inhibition of the HKII-mitochondria association led to a complete
reversal of this phenotype (Fig. 5d). Similar results were obtained in in-
fected primary cells treated with N-HKII (10 μM), TNF-α, (50 ng/ml)
and cycloheximide (10 μg/ml) from 24 h p.i. for 8 h (Supplementary
Fig. S4b). Finally, we used a specific antibody against cleaved caspase-
3 as an alternative readout for apoptosis (Fig. 5e). HeLa cells infected
for 24h p.i. were treated with 20μM N-HKII, 50ng/ml TNF-α and
10μg/ml cycloheximide for 5h. Although CTL2 infection alone conferred
resistance to TNF-α-induced apoptosis, inhibiting the HKII-mitochon-
dria interaction with N-HKII peptide was sufficient to reverse this phe-
notype (Fig. 5e and f) and induce apoptosis in over 90% of cells.
Collectively, our data show that the CTL2-induced apoptosis resistance
in host cells depends on the association of HKII with mitochondria.ncrease of PDPK1 phosphorylated at Ser-241 compared to total PDPK1 at 24 and 48 h p.i. in
es from a) were quantified and normalized to corresponding band densities of the β-actin
ted asmean fold change± SEM, *p b 0.05, t-test, n=3. c) CTL2 infection increases levels of
in HeLa cells. PDPK1 phosphorylated at Ser-241, IncA and nuclei were labelled with Cy3-
s are CTL2 inclusions. d) Monolayers of fallopian tube mesenchymal stem cells, infected
PDPK1 phosphorylated at Ser-241 and DAPI. Results were similar to c). Scale bar: 30 μm.
belled with antibodies against Chlamydia trachomatis, PDPK1 phosphorylated at Ser-241
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Fig. 3. PDPK1 activation precedes MYC stabilization and is essential for the formation of infectious progeny. a)Western blot showing reduced levels of phosphorylated PDPK1, total MYC
and MYC phosphorylated at Ser-62 in whole cell lysates prepared from cells infected with CTL2 for 48 h (MOI 1) and treated with the inhibitor BX912 (10 μM) 12 h p.i. for 36 h. β-actin
served as loading control. b) The band densities from a) were quantified and normalized to corresponding band densities of the β-actin loading control. Alterations in expression levels
compared to non-infected controls are represented as mean fold change ± SEM, *p b 0.05, t-test, n = 3. c) Treatment with BX912 (10 μM) 12 h p.i. for 36 h reduces levels of
phosphorylated PDPK1 in HeLa cells infected with CTL2 (MOI 0.5). Phosphorylated PDPK1 and nuclei were labelled with anti-phosphorylated PDPK1 antibody and DAPI. Scale bar: 30
μm. d) HeLa cells were infected with CTL2 (MOI 0.5), treated with BX912 (10 μM) from 12 h p.i. and the generation of infectious EBs determined by infectivity assay at 48 h. p.i.
Results are depicted as mean ± SD normalized to controls of three independent experiments; p b 0.0001, t-test.
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Herewe demonstrate a functional link between PDPK1 andHKII.We
show that PDPK1-MYC signaling is activated in cells infected with CTL2
and that this activation is essential for increased expression of HKII and
its mitochondrial association. Interestingly, forced dissociation of HKII
from mitochondria rendered cells sensitive to apoptosis, and blocking
of the pathway at the level of PDPK1, MYC, or HKII led to impaired bac-
terial growth. Evidently, in order to replicate productively, CTL2 not
only has to keep host cells alive but also needs to reprogram their me-
tabolism to secure sufficient nutrients for its growth. In healthy tissues,
induction of aerobic glycolysis and inactivation of cell cycle checkpoints
occur in rapidly proliferating cells and depend on growth factor signal-
ing. However, a limited supply of glycolytic substrates or insufficient
generation of ATP tomeet the cell's energy requirementswill trigger ap-
optosis (Izyumov et al., 2004; Okoshi et al., 2008). Under the condition
of cellular transformation the oncogenic kinase PDPK1 has been found
to be overexpressed and hyperactivated (Fyffe and Falasca, 2013). Our
analyses uncover a startling similar phenotype of CTL2-infected cells
in that infection activated two intrinsically oncogenic proteins, PDPK1
and MYC.
The PI3K pathway plays a central role in regulating cell survival
(Kennedy et al., 1997; Khwaja et al., 1997) and is considered to be the
main signaling cascade associatedwith the ability of Chlamydia to inhib-
it apoptosis induction by various stimuli, including staurosporine, TNF-
α, or etoposide (Verbeke et al., 2006). Chlamydia trachomatis-infected
cells also exhibit increased levels of HIF-1α and subsequently Mcl-1,
which blocks apoptosis at the mitochondrial level (Sharma et al.,
2011). Here we show that an important signaling component of thePI3K pathway, PDPK1, promotes apoptosis resistance via MYC stabiliza-
tion through phosphorylation at Ser-62. PDPK1 is a master regulator
with multiple roles in metabolism, proliferation and cell survival
(Raimondi and Falasca, 2011). MYC stabilization in turn leads to upreg-
ulation of HKII. The expression level and location of HKII are crucial for a
proper balance of metabolism and cell survival. The mitochondria-HKII
association favorably influences mitochondrial energetics and cell sur-
vival by preventing pro-apoptotic Bak and Bax oligomerization and
binding at the level of the mitochondrion (Robey and Hay, 2006). It is
also critical for preventing cytochrome c release and apoptosis, which
is regulated by the PI3K cascade (Kennedy et al., 1999). Recently, it
has been shown that Chlamydia preserves mitochondrial integrity
through upregulation of miR-30c, which downregulates p53 to ensure
its normal development inside the host (Chowdhury et al., 2017). Our
previous observation that restoring p53 levels in infected cells with
Nutlin3a treatment was unable to fully re-sensitize cells to apoptotic
stimuli (Gonzalez et al., 2014) strongly suggests that additional mecha-
nisms are employed by the pathogen to suppress apoptosis. In support
of this, we found that chemically removing HKII from mitochondria
had a severe impact on pathogen replication and fully re-sensitized in-
fected cells to TNF-α induced apoptosis.
This observation also has broader implications. Activation of
PDPK1-MYC-HKII signaling during CTL2 infection is likely to play a
direct role in metabolic reprogramming. MYC regulates several
other genes involved in glucose metabolism, in particular glucose
transporter 1 (Osthus et al., 2000). HKII plays a critical role in main-
taining the gradient required for glucose entry into the cell by cata-
lyzing the first step in glucose metabolism to generate glucose-6-
phosphate (Dang et al., 2008). This critical metabolite can serve as
Fig. 4.MYC-HKII axis is crucial for bacterial development. a) Western blotting analysis showing that in HeLa cells infected with CTL2 (MOI 1) and treated with BX912 (10 μM) for 36 h,
induction of total HKII protein expression is reduced compared to control cells. Samples were collected at 48 h p.i., β-actin served as loading control. b) The band densities from a)
were quantified and normalized to corresponding band densities of the β-actin loading control. Alterations in expression levels compared to non-infected controls are represented as
mean fold change ± SEM, *p b 0.05, t-test, n= 3. c) HeLa cells were infected with CTL2 (MOI 0.5) treated with different doses of JQ1 from 10 h p.i. and the generation of infectious EBs
determined via infectivity assay. Results are depicted as mean percentage ± SD normalized to controls of three independent experiments. *p b 0.05 ***p b 0.001, one-way ANOVA,
Dunnett's multiple comparison test. d) Western blot showing that in HeLa cells infected with CTL2 (MOI 1) HKII and MYC protein levels are significantly increased by 48 h p.i.
compared to control cells. This upregulation was significantly inhibited by JQ1 (20 μM for 44 h). β-actin served as loading control. e) The band densities from d) were quantified and
normalized to corresponding band densities of the β-actin loading control. Alterations in expression levels compared to non-infected controls are represented as mean fold change ±
SEM, *p b 0.05, t-test, n = 3. f) Western blot showing reduced induction of total MYC and HKII protein expression in HeLa cells transfected with siRNA specific for MYC or HKII,
compared to luciferase transfected CTL2-infected (MOI 1) whole cell lysates. Samples were collected 48 h p.i., β-actin served as loading control. g) HeLa cells transfected as shown in f)
infected with CTL2 (MOI 1) were examined for generation of infectious EBs by infectivity assay. Results are depicted as mean ± SD normalized to controls of three independent
experiments; ***p b 0.001, ****p b 0.0001, one-way ANOVA, Dunnett's multiple comparison test.
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ysis, as well as for nucleotide biosynthesis by PPP. Enhanced glucose
uptake and lactate production has indeed been observed in Chlamyd-
ia trachomatis-infected cells (Ojcius et al., 1998). Further, enhanced
expression of glucose-6-phosphate dehydrogenase, the key enzyme
of the PPP, has been shown to be a central element in the chlamydial
life cycle that reprograms the host cell metabolism in support of bac-
terial development (Gehre et al., 2016; Siegl et al., 2014). In congru-
ence, our results show that increased mitochondrial HKII is required
for CTL2 to complete its life-cycle.
In addition, Akt, another kinase required for apoptosis inhibition
during Chlamydia trachomatis infection (Verbeke et al., 2006), con-
verges onto MYC signaling during metabolic reprogramming, by en-
hancing the activity of both HKII and glucose transporters (Robey and
Hay, 2006; Wieman et al., 2007). This suggests that activation of
PDPK1 during Chlamydia trachomatis infection acts as a master switch
modulating Akt (Verbeke et al., 2006), p53 (Gonzalez et al., 2014;Siegl et al., 2014), and HKII, to ensure host cells are able to meet the
bacteria's metabolic requirements without triggering apoptosis.
The fact that Chlamydia trachomatis infection leads to degradation of
themaster tumor suppressor p53 is particularly poignant in the context
of MYC stabilization, as under normal conditions balance of these two
pathways is crucial for preventing tumorigenesis, and p53 normally re-
pressesMYC transcription (Sachdeva et al., 2009). They constitute two
of the most significant tumor related genes in the human genome, and
are increasingly linked to effects on host metabolism and cell survival.
Inhibition of p53 is known to enhance theWarburgmetabolism, charac-
teristic of rapidly proliferating and cancer cells – directing metabolic
pathways to aerobic glycolysis and the PPP – both of which are benefi-
cial also for Chlamydia trachomatis growth (Eisenreich et al., 2013;
Siegl et al., 2014).
Several therapeutic inhibitors have been developed to counteract
the fateful role of deregulated MYC activation in human cancers (Stine
et al., 2015). Use of the small molecule bromodomain inhibitor JQ1,
Fig. 5. CTL2 enhances HKII-mitochondria association to induce anti-apoptotic effect. a)Western blot ofmitochondrial and cytosolic fractions from infected cells and controls showing that
in infected cells with CTL2 (MOI 1)HKII protein levels aremarkedly increased by 48 h p.i. and translocated into themitochondria compared to control cells. VDAC served as loading control
for the mitochondrial fraction. b) HKII expression levels (cytosolic and mitochondria fractions) were quantified from infected and non-infected cells. Log HKII expression (mitochondria/
cytosolic) from infected and non-infected controls are represented asmean fold change± SEM, *p b 0.05, t-test, n=3. c)HeLa cellswere infectedwith CTL2 (MOI 1) treatedwith different
doses of clotrimazole from24h p.i. and the generation of infectious EBs determined via infectivity assay at 48 h p.i. Results are depicted asmean percentage± SDnormalized to controls of
three independent experiments; ***p b 0.001, one-way ANOVA, Dunnett's multiple comparison test. d) The extent of apoptosis induced by TNF-α treatment was analyzed by western
blotting using antibodies to cleaved PARP and caspase 3 in HeLa cells infected with CTL2 (MOI 1). Infected cells showed greatly reduced levels of cleaved PARP and caspase 3.
Treatment with a peptide inhibitor of HKII (20 μM) for 5 h fully sensitized cells to the levels seen in non-infected control cells. β-actin served as loading control. e) HeLa cells infected
with CTL2 (MOI 1) and immunolabelled for cleaved caspase-3 (green) showed markedly fewer positive cells upon TNF-α treatment. HKII peptide inhibitor treatment (20 μM) for 5 h
largely restored the number of cleaved caspase-3-positive cells. CTL2 inclusions and nuclei were labelled with anti-Chlamydia trachomatis antibody (red) and Hoechst (blue). f)
Quantitative analysis of the number of cleaved caspase-3-positive nuclei per image (12 images) in infected HeLa cells treated with HKII peptide inhibitor during apoptosis induction
with TNF-α and cycloheximide, shows that HKII peptide inhibitor significantly increases the number of apoptotic nuclei in infected cell populations. Results are depicted as mean ±
SD; ***p b 0.001, t-test, n= 3.
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inhibiting cancer cell viability (Jung et al., 2015). In our setting, genetic
and pharmacological means to inhibit MYC and PDPK1 also block chla-
mydial replication, suggesting that infected cells may be susceptible to
therapies targeting the PDPK1-MYC axis via inhibition of the majormetabolic regulator HKII. The finding that CTL2 activates the PDPK1-
MYC-HKII axis in host cells increases our understanding of how CTL2
survives in its intracellular niche despite its reduced genome size and
how it prevents the host cell from outstripping its nutrient supply as in-
fection progresses.
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